Page 23 - Aet News Today

As healthcare continues to evolve, discharge coordination software will play an increasingly important role in bridging the gap between hospital care and home care, ensuring that NICU graduates and their families receive the comprehensive support they need to thrive.

In an interview last week, Larry Cohen — CEO of Health 2047, the American Medical Association’s venture studio — noted that digital health programs have proven to do a good job of improving patient outcomes — but only for certain groups. As technology continues to advance, he urged healthcare leaders not to underestimate the effectiveness of engaging patients by having boots on the ground.

Gilead Sciences said even though Trodelvy missed the main goal of its Phase 3 test in non-small cell lung cancer, the drug’s preliminary results show numerical improvement in patients whose disease did not respond to prior treatment with immunotherapy. The company plans to discuss with regulators a possible path forward in these patients.

Turquoise Health closed a $30 million Series B round, which brings its total funding to date to $55 million. The San Diego-based startup, which has more than 160 customers, sells a platform that makes it easier for hospitals and payers to comply with price transparency regulations.

In 2024, the weight loss market finds itself at a crossroads, grappling with pivotal questions that will shape the future. The winners will prioritize affordable lifelong care, scalable coaching and support, and a diverse set of solutions that give people second and third chances along their weight loss journeys.

Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.

Adoption of value-based care has been slower in rural communities. With many rural providers struggling to even stay afloat, it can be difficult to switch to value-based care, according to one healthcare executive.

No matter the outcome, it’s certain that the cost of drugs will not be an issue easily resolved anytime soon even though several other states also have laws allowing for drug imports.

Exceptional awareness levels help hospitals improve operational efficiency and can also help health systems increase capacity, improve access to care, achieve higher profitability and improve margins.

In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema. If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals.